Administration of VEGF receptor tyrosine kinase inhibitor increases VEGF production causing angiogenesis in human small-cell lung cancer xenografts

International Journal of Oncology

Volumn 33, Issue 3, 2008, Pages 525-532

  Sasaki, Takaaki ^a   Tanno, Sachie ^a   Shibukawa, Kiyoko ^a   Osanai, Shinobu ^a   Kawabe, Junichi ^a   Ohsaki, Yoshinobu ^a  

^a ASAHIKAWA MEDICAL COLLEGE   (Japan)

Author keywords

Anti angiogenic therapy strategy; Microvessel counts; Small cell lung cancer; Tyrosine kinase inhibitor; Vascular endothelial growth factor; VEGF receptor

Indexed keywords

CD31 ANTIGEN; PROTEIN TYROSINE KINASE INHIBITOR; VANDETANIB; VASCULOTROPIN; VASCULOTROPIN RECEPTOR; VASCULOTROPIN RECEPTOR 2; N (4 BROMO 2 FLUOROPHENYL) 6 METHOXY 7 ((1 METHYLPIPERIDIN 4 YL)METHOXY)QUINAZOLIN 4 AMINE; N-(4-BROMO-2-FLUOROPHENYL)-6-METHOXY-7-((1-METHYLPIPERIDIN-4-YL)METHOXY)QUINAZOLIN-4-AMINE; PIPERIDINE DERIVATIVE; PROTEIN KINASE INHIBITOR; QUINAZOLINE DERIVATIVE; VASCULOTROPIN A;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER SIZE; CELL DEATH; CELL PROLIFERATION; CONTROLLED STUDY; DOSE RESPONSE; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; LOW DRUG DOSE; LUNG SMALL CELL CANCER; MICROVASCULATURE; MOUSE; NICK END LABELING; NONHUMAN; PRIORITY JOURNAL; STAINING; TREATMENT DURATION; TUMOR VASCULARIZATION; TUMOR XENOGRAFT; ANIMAL; BIOSYNTHESIS; DRUG ANTAGONISM; DRUG EFFECT; DRUG SCREENING; LUNG TUMOR; METABOLISM; NECROSIS; NEOVASCULARIZATION (PATHOLOGY); REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SMALL CELL CARCINOMA; TUMOR CELL LINE; VASCULARIZATION;

ANIMALS; APOPTOSIS; CARCINOMA, SMALL CELL; CELL LINE, TUMOR; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; IN SITU NICK-END LABELING; LUNG NEOPLASMS; MICE; NECROSIS; NEOVASCULARIZATION, PATHOLOGIC; PIPERIDINES; PROTEIN KINASE INHIBITORS; QUINAZOLINES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 54849186800     PISSN: 10196439     EISSN: None     Source Type: Journal    
DOI: 10.3892/ijo_00000036     Document Type: Article

References (42)

1. Yarden Y and Sliwkowski MX: Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2: 127-137, 2001.
2. Moulder SL, Yakes FM, Muthuswamy SK, et al: Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo. Cancer Res 61: 8887-8895, 2001.
3. Lee D and Heymach JV: Emerging antiangiogenic agents in lung cancer. Clin Lung Cancer 7: 304-308, 2006.
4. Holden SN, Eckhardt SG, Basser R, et al: Clinical evaluation of ZD6474, an orally active inhibitor of VEGF and EGF receptor signaling, in patients with solid, malignant tumors. Ann Oncol 16: 1391-1397, 2005.
5. Tamura T, Minami H, Yamada Y, et al: A phase I dose-escalation study of ZD6474 in Japanese patients with solid, malignant tumors. J Thorac Oncol 1: 1002-1009, 2006.
6. Heymach JV, Johnson BE, Prager D, et al: Randomized, placebo-controlled phase II study of vandetanib plus docetaxel in previously treated non small-cell lung cancer. J Clin Oncol 25: 4270-4277, 2007.
7. Tanno S, Ohsaki Y, Nakanishi K, et al: Human small cell lung cancer cells express functional VEGF receptors, VEGFR-2 and VEGFR-3. Lung Cancer 46: 11-19, 2004.
8. Pluda JM: Tumor-associated angiogenesis: mechanisms, clinical implications and therapeutic strategies. Semin Oncol 24: 203-218, 1997.
9. Lee AH, Happerfield LC, Bobrow LG, et al: Angiogenesis and inflammation in invasive carcinoma of the breast. J Clin Pathol 50: 669-673, 1997.
10. Folkman J: Angiogenesis in cancer, vascular, rheumatoid and other diseases. Nat Med 1: 27-31, 1995.
11. Des Guetz G, Uzzan B, Nicolas P, et al: Microvessel density and VEGF expression are prognostic factors in colorectal cancer. Meta-analysis of the literature. Br J Cancer 94: 1823-1832, 2006.
12. Beecken WD, Fernandez A, Joussen AM, et al: Effect of anti-angiogenic therapy on slowly growing, poorly vascularized tumors in mice. J Natl Cancer Inst 93: 382-387, 2001.
13. Hansen-Algenstaedt N, Stoll BR, Padera TP, et al: Tumor oxygenation in hormone-dependent tumors during vascular endothelial growth factor receptor-2 blockade, hormone ablation and chemotherapy. Cancer Res 60: 4556-4560, 2000.
14. Jain RK, Safabakhsh N, Sckell A, et al: Endothelial cell death, angiogenesis, and microvascular function after castration in an androgen-dependent tumor: role of vascular endothelial growth factor. Proc Natl Acad Sci USA 95: 10820-10825, 1998.
15. Lee CG, Heijn M, Di Tomaso E, et al: Anti-vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions. Cancer Res 60: 5565-5570, 2000.
16. Morgensztem D and Govindan R: Clinical trials of antiangiogenic therapy in non-small cell lung cancer: focus on bevacizumab and ZD6474. Expert Rev Anticancer Ther 6: 545-551, 2006.
17. Prewett M, Huber J, Li Y, et al: Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors. Cancer Res 59: 5209-5218, 1999.
18. Yuan F, Chen Y, Dellian M, et al: Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an anti-vascular endothelial growth factor/ vascular permeability factor antibody. Proc Natl Acad Sci USA 93: 14765-14770, 1996.
19. Checkley D, Tessier J, Kendrew J, et al: Use of dynamic contrast-enhanced MRI to evaluate acute treatment with ZD6474, a VEGF signalling inhibitor, in PC-3 prostate tumours. Br J Cancer 89: 1889-1895, 2003.
20. Taguchi F, Koh Y, Koizumi F, et al: Anticancer effects of ZD6474, a VEGF receptor tyrosine kinase inhibitor, in gefitinib ('Iressa')-sensitive and resistant xenograft models. Cancer Sci 95: 984-989, 2004.
21. Wedge SR, Ogilvie DJ, Dukes M, et al: ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. Cancer Res 62: 4645-4655, 2002.
22. Williams KJ, Telfer BA, Brave S, et al: ZD6474, a potent inhibitor of vascular endothelial growth factor signaling, combined with radiotherapy: schedule-dependent enhancement of antitumor activity. Clin Cancer Res 10: 8587-8593, 2004.
23. Ciardiello F, Caputo R, Damiano V, et al: Antitumor effects of ZD6474, a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor receptor tyrosine kinase. Clin Cancer Res 9: 1546-1556, 2003.
24. Lynch TJ, Bell DW, Sordella R, et al: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350: 2129-2139, 2004.
25. Paez JG, Janne PA, Lee JC, et al: EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304: 1497-1500, 2004.
26. Tamura K and Fukuoka M: Gefitinib in non-small cell lung cancer. Expert Opin Pharmacother 6: 985-993, 2005.
27. Yano S, Shinohara H, Herbst RS, et al: Expression of vascular endothelial growth factor is necessary but not sufficient for production and growth of brain metastasis. Cancer Res 60: 4959-4967, 2000.
28. Dias S, Hattori K, Zhu Z, et al: Autocrine stimulation of VEGFR-2 activates human leukemic cell growth and migration. J Clin Invest 106: 511-521, 2000.
29. Shushanov S, Bronstein M, Adelaide J, et al: VEGFc and VEGFR3 expression in human thyroid pathologies. Int J Cancer 86: 47-52, 2000.
30. Tanno S, Ohsaki Y, Nakanishi K, et al: Small cell lung cancer cells express EGFR and tyrosine phosphorylation of EGFR is inhibited by gefitinib ('Iressa', ZD1839). Oncol Rep 12: 1053-1057, 2004.
31. Semenza GL: Hypoxia, clonal selection and the role of HIF-1 in tumor progression. Crit Rev Biochem Mol Biol 35: 71-103, 2000.
32. Arao T, Fukumoto H, Takeda M, et al: Small in-frame deletion in the epidermal growth factor receptor as a target for ZD6474. Cancer Res 64: 9101-9104, 2004.
33. Camp ER, Summy J, Bauer TW, et al: Molecular mechanisms of resistance to therapies targeting the epidermal growth factor receptor. Clin Cancer Res 11: 397-405, 2005.
34. Engelman JA, Zejnullahu K, Mitsudomi T, et al: MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316: 1039-1043, 2007.
35. Ciardiello F, Bianco R, Caputo R, et al: Antitumor activity of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in human cancer cells with acquired resistance to antiepidermal growth factor receptor therapy. Clin Cancer Res 10: 784-793, 2004.
36. Morelli MP, Cascone T, Troiani T, et al: Anti-tumor activity of the combination of cetuximab, an anti-EGFR blocking monoclonal antibody and ZD6474, an inhibitor of VEGFR and EGFR tyrosine kinases. J Cell Physiol 208: 344-353, 2006.
37. Casanovas O, Hicklin DJ, Bergers G, et al: Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell 8: 299-309, 2005.
38. Noguera-Troise I, Daly C, Papadopoulos NJ, et al: Blockade of D114 inhibits tumour growth by promoting non-productive angiogenesis. Nature 444: 1032-1037, 2006.
39. Asahara T, Murohara T, Sullivan A, et al: Isolation of putative progenitor endothelial cells for angiogenesis. Science 275: 964-967, 1997.
40. Lyden D, Hattori K, Dias S, et al: Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. Nat Med 7: 1194-1201, 2001.
41. Rafii S, Lyden D, Benezra R, et al: Vascular and haematopoietic stem cells: novel targets for anti-angiogenesis therapy? Nat Rev Cancer 2: 826-835, 2002.
42. Beaudry P, Force J, Naumov GN, et al: Differential effects of vascular endothelial growth factor receptor-2 inhibitor ZD6474 on circulating endothelial progenitors and mature circulating endothelial cells: implications for use as a surrogate marker of antiangiogenic activity. Clin Cancer Res 11: 3514-3522, 2005.